Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9699976 | 0.85 | LOXL2 (0.56) | LOXL2CYP4F2CYP4A11BCL2FOLH1 | |
| SCHEMBL126284 | 0.83 | LOXL2 (0.74) | LOXL2CYP4F2CYP4A11FOLH1SLC7A5 | |
| SCHEMBL5925757 | 0.82 | TDP1 (0.46) | LOXL2CYP4F2CYP4A11 | |
| SCHEMBL27971856 | 0.81 | LOXL2 (0.53) | LOXL2CYP4F2CYP4A11BCL2SMYD3 | |
| SCHEMBL13291593 | 0.81 | CYP4F2 (0.62) | LOXL2CYP4F2CYP4A11SLC7A5MEP1B | |
| SCHEMBL27595257 | 0.81 | LOXL2 (0.53) | LOXL2CYP4F2CYP4A11BCL2SMYD3 | |
| SCHEMBL12814230 | 0.81 | LOXL2 (0.53) | LOXL2CYP4F2CYP4A11BCL2FOLH1 | |
| SCHEMBL129801 | 0.81 | CYP4F2 (0.71) | LOXL2CYP4F2CYP4A11MEP1BSMN1; SMN2 | |
| SCHEMBL27953652 | 0.81 | LOXL2 (0.53) | LOXL2CYP4F2CYP4A11BCL2FOLH1 | |
| SCHEMBL26042186 | 0.81 | LOXL2 (0.53) | LOXL2CYP4F2CYP4A11BCL2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | LOXL2 3239/4885CYP4F2 519/4885CYP4A11 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.